Tocilizumab biosimilar (GENERIUM Pharmaceuticals)

托珠单抗生物类似药 (GENERIUM Pharmaceuticals)

Report date: 2024/04/23 10:49:13

Base Information

Drug NameTocilizumab biosimilar (GENERIUM Pharmaceuticals)
Drug Alias NameComplarate®GNR-087
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesGenerium Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesGenerium Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A